secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001104659-25-096946
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva presents preclinical data for VCN-12 oncolytic adenovirus at ESGCT congress
--------------------------------------------------------------------------------

- VCN-12, derived from VCN-01, armed with transgenes to improve tumor lysis, stroma degradation, and antitumor immune response.
- Presentation at ESGCT 2025 in Seville, Spain on October 8, 2025, by co-founder Dr. Ramón Alemany.
- Preclinical study published in Human Gene Therapy shows intracranial VCN-01 administration feasible for brain tumor treatment.
- Study concludes findings provide strong rationale for VCN-01 development as therapy for brain tumors.
- No financial guidance or material changes to business operations announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925096946/0001104659-25-096946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925096946/tm2528055d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-096946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer